Renovacor Announces Upcoming Presentation at Keystone Symposia’s Heart Failure: Mechanisms and Therapies Conference

Rhea-AI Summary

Renovacor, a biotechnology firm (NYSE: RCOR), is set to showcase groundbreaking preclinical research at the Keystone Symposia’s Heart Failure Conference from September 28 - October 1, 2022, in Breckenridge, CO. The poster presentation, led by Dr. Valerie Myers, will focus on cardiac dysfunction in a BAG3 haploinsufficiency mouse model of dilated cardiomyopathy. Renovacor aims to develop therapies targeting genetic causes of severe heart failure, enhancing patient lives through innovative precision treatments.

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Renovacor, Inc. (NYSE: RCOR), a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases, today announced that preclinical studies characterizing the progression of cardiac dysfunction and mortality in a BAG3 haploinsufficiency mouse model of dilated cardiomyopathy will be featured in an upcoming poster presentation at Keystone Symposia’s Heart Failure: Mechanisms and Therapies Conference. The conference is taking place from September 28 – October 1, 2022, at the Beaver Run Resort in Breckenridge, CO.

The poster (#2001), titled, “Progression of cardiac dysfunction and mortality in a Bcl2-associated athanogene-3 (BAG3) haploinsufficiency mouse model of dilated cardiomyopathy (DCM),” will be presented from 7:30 – 10:00 p.m. MST on September 30, 2022, during Poster Session 2. The poster’s presenting author is Valerie Myers, Ph.D., Senior Director of Preclinical Science at Renovacor.

About Renovacor

Renovacor is a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases. The company’s lead program in BAG3-associated dilated cardiomyopathy (DCM) uses gene transfer technology to address the monogenic cause of this severe form of heart failure. Renovacor’s vision is to bring life-changing therapies to patients living with serious genetic cardiovascular and related diseases, by developing medicines that target the underlying cause of disease and provide a transformative benefit and significant improvement to quality of life.

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. These forward-looking statements are based upon current estimates and assumptions of the Company and its management and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: competition, the ability of the company to grow and manage growth, maintain relationships with customers and suppliers and retain its management and key employees; the Company's ability to successfully advance its current and future product candidates through development activities, preclinical studies and clinical trials and costs related thereto; the Company’s ability to submit an IND related to REN-001 on its anticipated timeline, and any challenges related to the clearance of such IND by the FDA; the timing, scope and likelihood of regulatory filings and approvals, including final regulatory approval of our product candidates; changes in applicable laws or regulations; the possibility that the Company may be adversely affected by other economic, business or competitive factors, including inflationary pressures; the Company’s estimates of expenses and profitability; the evolution of the markets in which the Company competes; the ability of the Company to implement its strategic initiatives and continue to innovate its existing products; the ability of the Company to defend its intellectual property; the impact of the COVID-19 pandemic on the Company’s business, supply chain and labor force; and the risks and uncertainties described in the “Risk Factors” section of the Company's annual and quarterly and reports filed the Securities Exchange Commission. These filings identify and address important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Renovacor assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Renovacor gives no assurance that it will achieve its expectations.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220926005810/en/

Brooks Rahmer

Renovacor, Inc.

610-424-2627

ir@renovacor.com

Source: Renovacor, Inc.

FAQ

What will Renovacor present at the Keystone Symposia Conference 2022?

Renovacor will present a poster on the progression of cardiac dysfunction in a BAG3 haploinsufficiency mouse model of dilated cardiomyopathy.

When will Renovacor's poster presentation take place?

The poster presentation will occur on September 30, 2022, from 7:30 – 10:00 p.m. MST.

Who is leading the poster presentation for Renovacor?

The presentation will be led by Dr. Valerie Myers, Senior Director of Preclinical Science.

What is the focus of Renovacor's research presented at the conference?

The research focuses on cardiac dysfunction and mortality related to BAG3 haploinsufficiency in dilated cardiomyopathy.

Where is the Keystone Symposia’s Heart Failure Conference being held?

The conference is taking place at Beaver Run Resort in Breckenridge, CO.